SE Sampson, JF Costello and AP Sampson
Department of Respiratory Medicine, King's College School of Medicine and Dentistry, London, United Kingdom.

Leukotriene (LT) B4 is a potent leukocyte chemotaxin that increases bronchial responsiveness in animal models. In a double-blind, placebo- controlled crossover study we examined the effects of LTB4 on lung function, bronchial responsiveness, and blood leukocyte counts in six normal subjects and in six subjects with mild asthma who inhaled mean +/- SEM doses of 17.6 +/- 3.4 and 18.2 +/- 1.9 microg LTB4, respectively, or placebo. There were no significant changes in specific airway conductance or bronchial responsiveness in either normal subjects or asthmatics for as long as 24 h after inhalation. In the normal subjects, LTB4 rapidly reduced blood neutrophil counts to 19.8 +/- 6.3% of baseline at 5 min (p = 0.0003 compared with placebo), followed by a neutrophilia of 307 +/- 40% of baseline at 30 min (p = 0.007). Similar changes occurred in asthmatics, with a neutropenia at 5 min (69.6 +/- 5.8%; p = 0.003) and a neutrophilia at 30 min (183 +/- 17.2%; p = 0.037). The neutrophilia was not sustained in either subject group, with values being no different from that of placebo by 6 h. The asthmatics had significantly less neutropenia (p = 0.005) and less neutrophilia (p = 0.018) than did the normal subjects. Placebo inhalation had no effect on any parameter in either group. The smaller neutrophil responses in asthmatics may reflect desensitization of blood neutrophils in vivo because of chronic exposure to endogenous LTB4.

This article has been cited by other articles:

				L. Flamand, M. J. Tremblay, and P. Borgeat Leukotriene B4 Triggers the In Vitro and In Vivo Release of Potent Antimicrobial Agents J. Immunol., June 15, 2007; 178(12): 8036 - 8045. [Abstract] [Full Text] [PDF]

				M. Peters-Golden, C. Canetti, P. Mancuso, and M. J. Coffey Leukotrienes: Underappreciated Mediators of Innate Immune Responses J. Immunol., January 15, 2005; 174(2): 589 - 594. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				P. M. O'BYRNE Why Does Airway Inflammation Persist? Is It Leukotrienes? Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S186 - 187. [Full Text] [PDF]

				S.-E. DAHLEN Pharmacological Characterization of Leukotriene Receptors Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S41 - 45. [Full Text] [PDF]

				P. P Hood, T. P Cotter, J. F Costello, and A. P Sampson Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients Thorax, December 1, 1999; 54(12): 1075 - 1082. [Abstract] [Full Text]

				S. O'Sullivan, S.-E. Dahlen, K. Larsson, B.-M. Larsson, P. Malmberg, M. Kumlin, and L. Palmberg Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine Thorax, December 1, 1998; 53(12): 1041 - 1046. [Abstract] [Full Text]

				F. P. GÓMEZ, R. IGLESIA, J. ROCA, J. A. BARBERÁ, K. FAN CHUNG, and R. RODRIGUEZ-ROISIN The Effects of 5-Lipoxygenase Inhibition by Zileuton on Platelet-activating-factor-induced Pulmonary Abnormalities in Mild Asthma Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1559 - 1564. [Abstract] [Full Text]